Cassava Sciences Files 8-K on Financials
Ticker: FLNA · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cassava Sciences filed an 8-K on Nov 7, 2024, for financial reporting.
AI Summary
Cassava Sciences, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as submitting financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing is a routine disclosure for Cassava Sciences, Inc., providing updates on their financial condition and operational results to investors and the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial reporting and does not indicate any immediate or significant risks.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- November 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Austin, Texas (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within this excerpt.
What is the exact date of the earliest event reported?
The exact date of the earliest event reported is November 7, 2024.
What is Cassava Sciences, Inc.'s principal executive office address?
The principal executive offices are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What is the Commission File Number for Cassava Sciences, Inc.?
The Commission File Number for Cassava Sciences, Inc. is 001-41905.
What is the SIC code for Cassava Sciences, Inc.?
The Standard Industrial Classification (SIC) code for Cassava Sciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-07 08:10:10
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_110724.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 66KB
- 0001171843-24-006089.txt ( ) — 285KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_110724_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 7, 2024, the Registrant issued a press release announcing financial results for the quarter ended September 30, 2024, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated November 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. a Delaware corporation Date: November 7, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer